Latest news with #TropisID
Business Wire
18 hours ago
- Health
- Business Wire
WHO and UNICEF to Launch Polio Vaccination Campaign in Afghanistan with PharmaJet
GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that the WHO prequalified Tropis ID delivery system will be used to support a polio eradication campaign sponsored by the National Emergency Operation Center (NEOC) Afghanistan, UNICEF, WHO, and other GPEI partners starting in August 2025. Focused on the Eastern region of Afghanistan, the campaign will deploy Tropis ID to administer 1.3 million fractional doses of inactivated polio vaccine (fIPV) to children ages 5 and under in parallel to oral polio vaccine (OPV) administration as part of a WHO-recommended strategy to boost humoral and mucosal immunity. Poliovirus has been eliminated in most parts of the world due to widespread vaccination campaigns, but it continues to circulate in Afghanistan and Pakistan. In 2024, wild poliovirus type 1 (WPV1) transmission rose significantly in Afghanistan. The use of Tropis ID enables site-to-site immunization, a strategy where vaccination services are offered at multiple, convenient locations. This approach is expected to help increase immunization coverage, particularly in high-risk areas. The Technical Advisory Group (TAG) on polio eradication endorsed the Afghanistan program's 'Strategic Reset' to optimize site-to-site vaccination, while stressing the need for stronger leadership, community acceptance, and broad government engagement. Including Tropis ID fIPV in this immunization program supports Afghanistan's polio eradication goals to eliminate persistent virus lineages in the East, prevent new WPV1 cases in the East and South Regions, and prevent local transmission in other parts of the country. 1 'We are pleased to be partnering with UNICEF, WHO, and NEOC Afghanistan in their continued efforts to eradicate polio,' said Paul LaBarre, Senior Vice President Global Business Development, PharmaJet. 'We aim to achieve high impact in the fight against poliovirus, including increased coverage, decreased costs, and high acceptability 2 previously seen with Tropis ID delivered fIPV in Pakistan, 2 Somalia, 3 and Nigeria 4.' Refer to Instructions for Use to ensure safe injections and to review risks. About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis ® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About the NEOC Afghanistan NEOC Afghanistan is led by the Ministry of Public Health and the core members are WHO, UNICEF, BMGF, CDC, Rotary International, Core Group of Polio Project (CGPP), EPI manager and the National Polio Focal Point. About the Global Polio Eradication Initiative (GPEI) 5 The Global Polio Eradication Initiative is a public-private partnership led by national governments with six partners – the World Health Organization (WHO), Rotary International, the US Centers for Disease Control and Prevention (CDC), the United Nations Children's Fund (UNICEF), Gates Foundation and Gavi, the vaccine alliance. Its goal is to eradicate polio worldwide. Launched in 1988 after the World Health Assembly passed a resolution to eradicate polio, the Global Polio Eradication Initiative, along with its partners, has helped countries to make huge progress in protecting the global population from this debilitating disease. As a result, the global incidence of polio has decreased by 99.9% since GPEI's foundation. An estimated 20 million people today are walking who would otherwise have been paralyzed by the disease, and more than 1.5 million people are alive, whose lives would otherwise have been lost. Now the task remains to tackle polio in its last few strongholds and get rid of the final 0.1% of polio cases including the two remaining endemic countries: Pakistan and Afghanistan.
Business Wire
a day ago
- Health
- Business Wire
WHO and UNICEF to Launch Polio Vaccination Campaign
GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that the WHO prequalified Tropis ID delivery system will be used to support a polio eradication campaign sponsored by the National Emergency Operation Center (NEOC) Afghanistan, UNICEF, WHO, and other GPEI partners starting in August 2025. Focused on the Eastern region of Afghanistan, the campaign will deploy Tropis ID to administer 1.3 million fractional doses of inactivated polio vaccine (fIPV) to children ages 5 and under in parallel to oral polio vaccine (OPV) administration as part of a WHO-recommended strategy to boost humoral and mucosal immunity. Poliovirus has been eliminated in most parts of the world due to widespread vaccination campaigns, but it continues to circulate in Afghanistan and Pakistan. In 2024, wild poliovirus type 1 (WPV1) transmission rose significantly in Afghanistan. The use of Tropis ID enables site-to-site immunization, a strategy where vaccination services are offered at multiple, convenient locations. This approach is expected to help increase immunization coverage, particularly in high-risk areas. The Technical Advisory Group (TAG) on polio eradication endorsed the Afghanistan program's 'Strategic Reset' to optimize site-to-site vaccination, while stressing the need for stronger leadership, community acceptance, and broad government engagement. Including Tropis ID fIPV in this immunization program supports Afghanistan's polio eradication goals to eliminate persistent virus lineages in the East, prevent new WPV1 cases in the East and South Regions, and prevent local transmission in other parts of the country. 1 'We are pleased to be partnering with UNICEF, WHO, and NEOC Afghanistan in their continued efforts to eradicate polio,' said Paul LaBarre, Senior Vice President Global Business Development, PharmaJet. 'We aim to achieve high impact in the fight against poliovirus, including increased coverage, decreased costs, and high acceptability 2 previously seen with Tropis ID delivered fIPV in Pakistan, 2 Somalia, 3 and Nigeria 4.' Refer to Instructions for Use to ensure safe injections and to review risks. About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis ® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About the NEOC Afghanistan NEOC Afghanistan is led by the Ministry of Public Health and the core members are WHO, UNICEF, BMGF, CDC, Rotary International, Core Group of Polio Project (CGPP), EPI manager and the National Polio Focal Point. About the Global Polio Eradication Initiative (GPEI) 5 The Global Polio Eradication Initiative is a public-private partnership led by national governments with six partners – the World Health Organization (WHO), Rotary International, the US Centers for Disease Control and Prevention (CDC), the United Nations Children's Fund (UNICEF), Gates Foundation and Gavi, the vaccine alliance. Its goal is to eradicate polio worldwide. Launched in 1988 after the World Health Assembly passed a resolution to eradicate polio, the Global Polio Eradication Initiative, along with its partners, has helped countries to make huge progress in protecting the global population from this debilitating disease. As a result, the global incidence of polio has decreased by 99.9% since GPEI's foundation. An estimated 20 million people today are walking who would otherwise have been paralyzed by the disease, and more than 1.5 million people are alive, whose lives would otherwise have been lost. Now the task remains to tackle polio in its last few strongholds and get rid of the final 0.1% of polio cases including the two remaining endemic countries: Pakistan and Afghanistan. 1 World Health Organization, Global Polio Eradication Initiative, Technical Advisory Group urges strong action to eradicate polio in Afghanistan, February 26, 2025 2 Daly, C et al, Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine (fIPV) in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability, Vaccine, Volume 38 Issue 8, 18 February, 2020, Pages 1893-1898 3 Nouh, K et al, Use of a fractional dose of inactivated polio vaccine (fIPV) to increase IPV coverage among children under 5 years of age in Somalia, Springer Nature Volume 2 article number 16 (2024) 4 Biya, O et al, Notes from the Field: House-to-House Campaign Administration of Inactivated Poliovirus Vaccine — Sokoto State, Nigeria, November 2022, CDC Morbidity and Mortality Weekly report, November 24, 2023 / 72(47);1290–1291 5 Global Polio Eradication Initiative, who we are:
Business Wire
05-06-2025
- Health
- Business Wire
Intradermal Vaccination over Intramuscular Standard of Care
GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that Vaccines has published the results of an implementation research study entitled Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria's routine immunization program: An implementation hybrid trial. 1 The study, funded by a multi-year, US$1.5 million grant from the USAID Development Innovation Ventures Program, in collaboration with the Nigeria National Primary Health Care Development Agency (NPHCDA), Jhpiego, PATH, Sydani Group and Johns Hopkins Bloomberg School of Public Health, aimed to comparatively evaluate the vaccine coverage, cost, feasibility and acceptability of using Tropis ID for fIPV delivery compared to the SoC in a routine immunization program. A household survey was completed in Kano and Oyo States following a six-month implementation with children aged 3 to 12 months. "This study demonstrates that Tropis ID can improve the patient and caregiver experience over the standard of care for routine immunizations, resulting in increased vaccine compliance, which is an important element in eradicating polio." Share This study is the first to measure coverage benefits of Tropis ID in RI settings, adding to the evidence of the value of needle-free intradermal delivery in the global pursuit of polio eradication. While Nigeria improved full regimen coverage from 33% in 2016 to 57% in 2022, 2 it is actively pursuing new approaches that may bring further improvements to coverage and reduce costs as the country prepares for transition from Gavi support, 3 while navigating funding reductions in global health programs. Tropis ID, a WHO pre-qualified needle-free delivery system, is an easy-to-use, precise, intradermal delivery method that has already been successfully used in campaign and house-to-house settings in high-risk polio environments, with over 12 million injections administered to date. 4 The Vaccines publication highlighted that when compared to the SoC, Tropis ID demonstrated: Increased coverage: IPV2 coverage was 11.2% higher. On a relative basis, this means the odds of receiving 2 doses of IPV are doubled when Tropis ID is used. Cost savings: Up to 47% total immunization costs savings can be realized when using Tropis ID for IPV delivery, 4 which equates to a potential savings for the Nigeria immunization program of ~US$50 million over a 5-year period. Acceptability: 97% of healthcare workers preferred Tropis ID for routine immunization, noting it is easy to operate, associated with less perceived discomfort by children during administration, and elicited a positive caregiver response. 'This study demonstrates that Tropis ID can improve the patient and caregiver experience over the standard of care for routine immunizations, resulting in increased vaccine compliance, which is an important element in eradicating polio,' said Paul LaBarre, Vice President Global Business Development, PharmaJet. 'With the added benefits of intradermal dose sparing and the associated cost savings, Tropis ID is an ideal immunization tool. We look forward to collaborating with other African partners to assess the benefits needle-free ID delivery can provide for their immunization programs.' Refer to Instructions for Use to ensure safe injections and to review risks. 1 Mohan, D et al, Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria's routine immunization program: An implementation hybrid trial, Vaccines,16 May 2025, 13(5), p.533 2 2023: A Critical Year for polio eradication efforts in northern Nigeria. Global Polio Eradication Initiative. 2023. (accessed on 21 March 2025) 3 Presentation of Evidence by the Polio Disease Working Group. Presented at the meeting of the Nigerian Immunization Technical Advisory Group, Abuja, Nigeria, 24 July 2018. 4 Data on file About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. Tropis ® ID has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. In 1988, the Global Polio Eradication Initiative (GPEI) was launched after a resolution passed by the World Health Assembly, with over 350,000 children recorded as having paralytic polio across 125 countries. The GPEI's goals are to detect and stop the spread of poliovirus and strengthen immunization programs globally. Post-eradication strategies, such as sustaining high vaccination rates and strengthening surveillance efforts, are important in the goal of eradicating polio. The GPEI Polio Eradication Strategy 2022–2026 set 2023 as a target year to interrupt all remaining type 1 wild poliovirus (WPV1) transmission (Goal One) and type 2 circulating vaccine-derived poliovirus (cVDPV) transmission (Goal Two), with the aim of reaching eradication by 2026.
Yahoo
05-06-2025
- Health
- Yahoo
Publication in Vaccines Highlights Important Benefits of PharmaJet® Tropis® Intradermal Vaccination over Intramuscular Standard of Care
Substantial Improvements in Coverage of IPV2. Vaccine coverage of the second dose of inactivated polio vaccine (IPV2) administered with Tropis ID increased by 11.2% compared to the standard of care (SoC, full dose delivered by needle and syringe intramuscular delivery). On a relative basis, the odds of receiving 2 doses of IPV are doubled when using Tropis ID. Preferred by Vast Majority of Healthcare Workers. Needle-free Tropis ID was the preferred method of vaccination for routine immunization (RI) as reported by 97% of healthcare workers surveyed, who cited that, compared to the SoC, Tropis ID was (i) easier to use (95%), and (ii) children experienced less discomfort (94%). Significant Cost Reductions. Incremental savings with needle-free could range from US$0.07 to US$1.00 per dose, with up to 47% total immunization cost savings compared to the SoC in a full-scale scenario. This equates to a potential savings of ~US$50 million over a 5-year period using Tropis ID for the Nigeria immunization program. GOLDEN, Colo., June 05, 2025--(BUSINESS WIRE)--PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that Vaccines has published the results of an implementation research study entitled Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria's routine immunization program: An implementation hybrid trial.1 The study, funded by a multi-year, US$1.5 million grant from the USAID Development Innovation Ventures Program, in collaboration with the Nigeria National Primary Health Care Development Agency (NPHCDA), Jhpiego, PATH, Sydani Group and Johns Hopkins Bloomberg School of Public Health, aimed to comparatively evaluate the vaccine coverage, cost, feasibility and acceptability of using Tropis ID for fIPV delivery compared to the SoC in a routine immunization program. A household survey was completed in Kano and Oyo States following a six-month implementation with children aged 3 to 12 months. This study is the first to measure coverage benefits of Tropis ID in RI settings, adding to the evidence of the value of needle-free intradermal delivery in the global pursuit of polio eradication. While Nigeria improved full regimen coverage from 33% in 2016 to 57% in 2022,2 it is actively pursuing new approaches that may bring further improvements to coverage and reduce costs as the country prepares for transition from Gavi support,3 while navigating funding reductions in global health programs. Tropis ID, a WHO pre-qualified needle-free delivery system, is an easy-to-use, precise, intradermal delivery method that has already been successfully used in campaign and house-to-house settings in high-risk polio environments, with over 12 million injections administered to date.4 The Vaccines publication highlighted that when compared to the SoC, Tropis ID demonstrated: Increased coverage: IPV2 coverage was 11.2% higher. On a relative basis, this means the odds of receiving 2 doses of IPV are doubled when Tropis ID is used. Cost savings: Up to 47% total immunization costs savings can be realized when using Tropis ID for IPV delivery,4 which equates to a potential savings for the Nigeria immunization program of ~US$50 million over a 5-year period. Acceptability: 97% of healthcare workers preferred Tropis ID for routine immunization, noting it is easy to operate, associated with less perceived discomfort by children during administration, and elicited a positive caregiver response. "This study demonstrates that Tropis ID can improve the patient and caregiver experience over the standard of care for routine immunizations, resulting in increased vaccine compliance, which is an important element in eradicating polio," said Paul LaBarre, Vice President Global Business Development, PharmaJet. "With the added benefits of intradermal dose sparing and the associated cost savings, Tropis ID is an ideal immunization tool. We look forward to collaborating with other African partners to assess the benefits needle-free ID delivery can provide for their immunization programs." Refer to Instructions for Use to ensure safe injections and to review risks. 1 Mohan, D et al, Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria's routine immunization program: An implementation hybrid trial , Vaccines,16 May 2025, 13(5), p.5332 2023: A Critical Year for polio eradication efforts in northern Nigeria. Global Polio Eradication Initiative. 2023. (accessed on 21 March 2025)3 Presentation of Evidence by the Polio Disease Working Group. Presented at the meeting of the Nigerian Immunization Technical Advisory Group, Abuja, Nigeria, 24 July 2018.4 Data on file About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. Tropis® ID has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About The Global Polio Eradication Strategy (GPEI) In 1988, the Global Polio Eradication Initiative (GPEI) was launched after a resolution passed by the World Health Assembly, with over 350,000 children recorded as having paralytic polio across 125 countries. The GPEI's goals are to detect and stop the spread of poliovirus and strengthen immunization programs globally. Post-eradication strategies, such as sustaining high vaccination rates and strengthening surveillance efforts, are important in the goal of eradicating polio. The GPEI Polio Eradication Strategy 2022–2026 set 2023 as a target year to interrupt all remaining type 1 wild poliovirus (WPV1) transmission (Goal One) and type 2 circulating vaccine-derived poliovirus (cVDPV) transmission (Goal Two), with the aim of reaching eradication by 2026. View source version on Contacts Nancy 1-888-900-4321 Option 3 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
